Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Current Deferred Revenue (2020 - 2022)

GeneDx Holdings has reported Current Deferred Revenue over the past 3 years, most recently at $40000.0 for Q4 2022.

  • Quarterly Current Deferred Revenue fell 91.54% to $40000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $40000.0 through Dec 2022, down 91.54% year-over-year, with the annual reading at $40000.0 for FY2022, 91.54% down from the prior year.
  • Current Deferred Revenue was $40000.0 for Q4 2022 at GeneDx Holdings, down from $100000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $2.8 million in Q1 2021 and troughed at $40000.0 in Q4 2022.
  • The 3-year median for Current Deferred Revenue is $493000.0 (2021), against an average of $1.0 million.
  • Year-over-year, Current Deferred Revenue tumbled 73.72% in 2021 and then plummeted 96.44% in 2022.
  • A 3-year view of Current Deferred Revenue shows it stood at $1.8 million in 2020, then tumbled by 73.72% to $473000.0 in 2021, then crashed by 91.54% to $40000.0 in 2022.
  • Per Business Quant, the three most recent readings for WGS's Current Deferred Revenue are $40000.0 (Q4 2022), $100000.0 (Q1 2022), and $473000.0 (Q4 2021).